UNSPSC 51362004: Zolazepam

This classification denotes a sedative and hypnotic with the molecular formula C14H13FN4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G1R474U58U, chemically known as 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)(1,4)diazepin-7(1h)-one but generally known as zolazepam, which bears US NIH Compound Identifier 35775. European Medicines Agency schedules Zolazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00175MIG. The term ZOLAZEPAM is an International Non-Proprietary Name.

UNSPSC 51362004 Zolazepam is a Commodity code that captures pharmaceutical active ingredients and finished drug products procured by state and local health agencies, but recent state and local opportunities show little activity directly aligned with this code's nominal scope. The three recent solicitations in the dataset address naloxone and safe drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). Only the Seminole County opportunity mentions a specific pharmaceutical product—naloxone—which differs from zolazepam in clinical application and regulatory classification. The issuing bodies span county health departments, state HHS agencies, and cooperative purchasing alliances serving multiple states, but none explicitly reference zolazepam procurement.

Geographic activity centers on Florida, Texas, and Minnesota based on recent postings, with the Minnesota MMCAP procurement extending to participating jurisdictions including Oregon. The Seminole County IFB for naloxone and safe drug deactivation systems (IFB60459723LAS) closed July 26, 2023, seeking 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to Sanford, Florida. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs rather than committing to specific pharmaceutical purchases. Minnesota's MMCAP RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026 with responses due March 26, 2026, represents the most active cooperative purchasing vehicle and includes manufacturers as primary bidders required to maintain wholesaler relationships and comply with cGMP and Drug Supply Chain Security Act standards. The code shows sparse recent alignment with zolazepam specifically; firms pursuing activity under this code should monitor state pharmaceutical procurement trends and cooperative purchasing RFPs focused on controlled substances and specialized pharmaceutical categories rather than broad generic-drug programs.